ArticleJCO oncology advances2026
Evaluating Minority Participation in Radiation Oncology Clinical Trials and the Impact of COVID-19 on Enrollment in a Large Integrated Academic Satellite Network.
Article in JCO oncology advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeSocial distancing and health care rationing during the COVID-19 pandemic exacerbated cancer disparities. It is important to understand the impact of ethnic representation in clinical trials. We investigated how COVID-19 disease influenced racial/ethnic representation in radiation oncology (RO) trials in a large integrated academic satellite, hypothesizing that the pandemic significantly affected minority participation.
methodsWe conducted an institutional review board-approved retrospective analysis of patients 18 years and older who enrolled in RO trials from March 2018 to August 2024 in a five-campus integrated academic satellite. Chi-square testing was used to compare variables across the COVID-19 periods. Statistical significance was considered for
resultsA total of 1,702 patients were enrolled in RO trials: 531 (31.2%) pre-COVID-19, 843 (49.5%) during COVID-19, and 328 (19.3%) post-COVID-19. Racial/ethnic makeup was 79% White and 21% non-White. There was an increase in minority participation during COVID-19 (147 [17.5%]) compared with pre-COVID-19 (71 [12.5%]) and post-COVID-19 (46 [14.0%]) although this increase was not statistically significant (
conclusionDespite abundant literature suggesting the exacerbation of racial disparities in trials during COVID-19, we observed an increase in minority representation. Travel restrictions and regionally focused recruitment might have played a role. Future research should explore strategies focused on expanding outreach initiatives and integrating telehealth and patient education to enhance participation. By prioritizing equitable access to trials, we can improve cancer care and enhance the distribution of benefits and risks and the generalizability of research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.